Elevance Health's earnings can rebound in 2026 as margins stabilize and core business segments contribute to performance, UBS said in a note on Monday.
The firm noted that Elevance recently lowered its 2025 earnings guidance by $4.50, primarily due to a 90-basis-point increase in its medical loss ratio, which implies $1.43 billion in added medical costs.
"Given where the company is exiting 2025 there appears to be a pathway towards a $30 to $34 starting point for 2026 EPS," the analysts said in the note.
UBS projects EPS could rise to $33.50 in 2026, supported by gains from commercial risk and ASO businesses.
UBS reiterated its buy rating on Elevance with a 12-month price target of $435.
Price: 286.33, Change: -2.77, Percent Change: -0.96
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。